Pharmaceutical Technology31m
XB-010 by Exelixis for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
XB-010 is under clinical development by Exelixis and currently in Phase I for Triple-Negative Breast Cancer (TNBC).
Pharmaceutical Technology33m
CLN-619 by Cullinan Therapeutics for Refractory Multiple Myeloma: Likelihood of Approval
CLN-619 is under clinical development by Cullinan Therapeutics and currently in Phase I for Refractory Multiple Myeloma.